Get startedLog in
    Picture of Viking Therapeutics logo

    VKTX — Viking Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeLarge CapNeutral
    All News

    Brief: Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Venture-Oral Dosing Trial Of Vk2735 Tablet Formulation In Patients With Obesity

    Picture of Viking Therapeutics logoViking Therapeutics
    19/08/2025 12:39
    Viking Therapeutics Inc VKTX.O:

VIKING THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 VENTURE-ORAL DOSING TRIAL OF VK2735 TABLET FORMULATION IN PATIENTS WITH OBESITY

VIKING THERAPEUTICS INC - STUDY ACHIEVES ENDPOINTS WITH SIGNIFICANT WEIGHT REDUCTION USING VK2735

VIKING THERAPEUTICS INC - UP TO 12.2% MEAN WEIGHT LOSS WITH VK2735 AFTER 13 WEEKS

VIKING THERAPEUTICS INC - VK2735 SHOWN TO BE SAFE AND WELL-TOLERATED IN 13-WEEK STUDY

Source text: ID:nPn8cWJYSa

Further company coverage: VKTX.O

    Recent news on Viking Therapeutics

    See all news